David has a BSc and PhD in Experimental Physics from St. Andrew’s University. His post-doctoral career included breast cancer research at the Churchill Hospital, Oxford. David’s research work on breast cancer at the Department of Radiology, Kuwait University further supported the concept of angiogenesis being a marker for breast cancer screening using an optical system. David returned to Scotland in 1996 and immediately set up Highland Innovation Centre Ltd to commercialise his research findings and develop the BREAST-i™.
In 1992, his research was recognised and commercialised through Aurora Instruments Ltd, a joint venture company between the University of Aberdeen, Scottish Development Agency and Castle Medical Supplies Ltd. In 1996, he set up Highland Innovation Centre Ltd to commercialise his research findings and develop the BREAST-i™. During this time, he also held the position of Honorary Senior Lecturer Biomedical Physics, University of Aberdeen, 1999-2008. Throughout his career, David has been the recipient of many awards for his work on angiogenesis detection with the most recent being the Winner of the SMART Award 1999 from the Scottish Executive. He was also recipient of a grant in 2015 from Highland and Island Enterprise to complete development of BREAST-i™.
The BREAST-i™ incorporates David’s many years of study and research to be the only patented state-of-the-art breast cancer self-examination device built upon his pioneering work on optical technology and angiogenesis which has created an affordable tool for early breast cancer detection.
David continues to offer his expert advice in an advisory role for BREAST-i™ innovation and R&D at GM Instruments Ltd, Irvine, Scotland, which manufacture the BREAST-i™. David is a Fellow of the Institute of Acoustics and Member of the Institute of Electrical Engineers and Chartered Engineer.